Orexigen® Therapeutics To Be Added to the NASDAQ Biotechnology Index
SAN DIEGO, May 14, 2012 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that it will be added to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective Monday, May 21, 2012.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB) and which also meet other eligibility criteria, including market value, average daily share volume, and seasoning as a public company. The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Contrave cardiovascular outcomes trial which the company plans to initiate this quarter. The Company’s other product candidate, Empatic(TM), has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
Orexigen Contact: Media Contact: McDavid Stilwell Denise Powell VP, Corporate Communications and Business Development WCG (858) 875-8629 (510) 703-9491
SOURCE Orexigen Therapeutics, Inc.